news
Lilly announces agreement to acquire Dermira for $1.1bn
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
List view / Grid view
Eli Lilly & Company
Filter the results
news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
news
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
23 August 2016 | By AstraZeneca
AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.
news
Lilly and Boehringer Ingelheim take on metastatic breast cancer
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
news
Jardiance reduces risk of progressive kidney disease in type 2 diabetes
14 June 2016 | By Victoria White, Digital Content Producer
Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease...
news
Jardiance data shows reduced risk of CV death in type 2 diabetes
13 June 2016 | By Victoria White, Digital Content Producer
New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes...
news
New data for Trulicity and Tradjenta in type 2 diabetes
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
news
New data for baricitinib in rheumatoid arthritis presented at EULAR
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
news
Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
news
Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
news
FDA grants Priority Review for olaratumab BLA
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
news
Positive topline results from a Phase Ib study of BioChaperone Lispro
28 April 2016 | By Victoria White, Digital Content Producer
Adocia and Lilly have announced positive topline results from a Phase Ib trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro...
news
EC grants marketing authorisation to Lilly’s ixekizumab
26 April 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults...
news
Jardiance to be investigated in chronic heart failure trials
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...